← All Eupraxia Pharmaceuticals INC filings

Eupraxia Pharmaceuticals INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
EPRX
Eupraxia Pharmaceuticals INC
SCHEDULE: Manchester Entities Adjust EuPhoria Pharmaceuticals Stake
Several Manchester entities and individuals have updated their beneficial ownership filings for EUPRAXIA PHARMACEUTICALS INC. common shares, with aggregate holdings now reported.
NASDAQ
EPRX
Eupraxia Pharmaceuticals INC
SCHEDULE: Manchester Management Discloses 7.7% Stake in Eupraxia
Manchester Management and associated parties have filed a Schedule 13G reporting a combined 7.7% beneficial ownership stake in Eupraxia Pharmaceuticals Inc.
NASDAQ
EPRX
Eupraxia Pharmaceuticals INC
SCHEDULE: Manchester Group Discloses 9.2% Stake in Eupraxia Pharma
Manchester Management entities and individuals James E. Besser and Morgan C. Frank have disclosed a significant beneficial ownership stake in Eupraxia Pharmaceuticals Inc., with Morgan C. Frank holding the largest individual percentage at 9.2%.
NASDAQ
EPRX
Eupraxia Pharmaceuticals INC
SCHEDULE: Robert Disbrow Reports 7% Stake in Eupraxia Pharma
Robert Disbrow has filed an amended Schedule 13G, reporting a beneficial ownership of 7.0% in Eupraxia Pharmaceuticals Inc. as of September 30, 2025.
NASDAQ
EPRX
Eupraxia Pharmaceuticals INC
SCHEDULE: Beutel, Goodman & Co Ltd. Discloses 8% Stake in EUPRAXIA
Beutel, Goodman & Co Ltd., a Canadian investment adviser, has disclosed an 8.02% beneficial ownership stake in EUPRAXIA PHARMACEUTICALS INC. common shares.
NASDAQ
EPRX
Eupraxia Pharmaceuticals INC
SCHEDULE: Manchester Group Discloses 10%+ Stake in Eupraxia Pharma
A group of Manchester entities and individuals have disclosed beneficial ownership exceeding 10% of Eupraxia Pharmaceuticals Inc.'s Common Shares.